[ Biovotion raises $13.48M in Series A ]
Biovotion has raised $13.48 million in Series A funding.
Founded in 2011, Biovotion provides clinical-grade wearable solutions based on the company’s know-how and IP in non-invasive physiological monitoring, including vital sign, hydration, and glucose monitoring, supporting users in keeping a healthy lifestyle, improving healthcare treatment outcomes, and aiming to reduce cost of health provisions.
The addition of a new corporate VC to the shareholder group solidifies Biovotion’s ambition to partner with those committed to driving digital transformation efforts in the medical and health industries. Biovotion continues to promote the decentralisation of healthcare provision, with a focus on empowering end users and patients in a highly scalable and bidirectional manner.
|Founder / CEO||Andreas Caduff|